80 related articles for article (PubMed ID: 20957419)
1. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Yokoyama H; Yano R; Kuroiwa H; Tsukada T; Uchida H; Kato H; Kasahara J; Araki T
Metab Brain Dis; 2010 Sep; 25(3):305-13. PubMed ID: 20957419
[TBL] [Abstract][Full Text] [Related]
2. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
3. The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Peng F; Lu L; Wei F; Wu D; Wang K; Tang J
Neuroreport; 2020 Apr; 31(6):456-465. PubMed ID: 32168102
[TBL] [Abstract][Full Text] [Related]
4. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.
Yokoyama H; Kuroiwa H; Kasahara J; Araki T
Acta Neurobiol Exp (Wars); 2011; 71(2):269-80. PubMed ID: 21731080
[TBL] [Abstract][Full Text] [Related]
5. Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.
Liu X; Wang C; Liu W; Song S; Fu J; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Neurochem Res; 2021 Sep; 46(9):2317-2332. PubMed ID: 34097239
[TBL] [Abstract][Full Text] [Related]
6. Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.
Li H; Feng Y; Chen Z; Jiang X; Zhou Z; Yuan J; Li F; Zhang Y; Huang X; Fan S; Wu X; Huang C
Pharmacol Res; 2021 Jan; 163():105220. PubMed ID: 33007422
[TBL] [Abstract][Full Text] [Related]
7. MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies.
Mustapha M; Mat Taib CN
Bosn J Basic Med Sci; 2021 Aug; 21(4):422-433. PubMed ID: 33357211
[TBL] [Abstract][Full Text] [Related]
8. Purple pitanga extract (Eugenia uniflora) attenuates oxidative stress induced by MPTP.
Fidelis EM; Savall ASP; Mello JD; Quines CB; Comis-Neto AA; Sampaio TB; Denardin CC; de Ávila DS; Rosa SG; Pinton S
Metab Brain Dis; 2023 Dec; 38(8):2615-2625. PubMed ID: 37921949
[TBL] [Abstract][Full Text] [Related]
9. Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
Dugan LL; Tian L; Quick KL; Hardt JI; Karimi M; Brown C; Loftin S; Flores H; Moerlein SM; Polich J; Tabbal SD; Mink JW; Perlmutter JS
Ann Neurol; 2014 Sep; 76(3):393-402. PubMed ID: 25043598
[TBL] [Abstract][Full Text] [Related]
10. Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats.
Meka ST; Bojja SL; Kumar G; Birangal SR; Rao CM
Eur J Pharmacol; 2023 Nov; 959():176067. PubMed ID: 37751833
[TBL] [Abstract][Full Text] [Related]
11. Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
Nurmaganbetov ZS; Arystan LI; Muldaeva GM; Haydargalieva LS; Adekenov SM
Pharmacol Rep; 2019 Dec; 71(6):1050-1058. PubMed ID: 31605892
[TBL] [Abstract][Full Text] [Related]
12. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
13. Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study.
Terada T; Bunai T; Hashizume T; Matsudaira T; Yokokura M; Takashima H; Konishi T; Obi T; Ouchi Y
Sci Rep; 2024 Feb; 14(1):4708. PubMed ID: 38409373
[TBL] [Abstract][Full Text] [Related]
14. Combination of Drugs and Cell Transplantation: More Beneficial Stem Cell-Based Regenerative Therapies Targeting Neurological Disorders.
Nishimura K; Takata K
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445753
[TBL] [Abstract][Full Text] [Related]
15. Zonisamide, an antiepileptic drug, alleviates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress.
Tian JH; Wu Q; He YX; Shen QY; Rekep M; Zhang GP; Luo JD; Xue Q; Liu YH
Acta Pharmacol Sin; 2021 Mar; 42(3):393-403. PubMed ID: 32647341
[TBL] [Abstract][Full Text] [Related]
16. The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Na
Hossain MM; Weig B; Reuhl K; Gearing M; Wu LJ; Richardson JR
Exp Neurol; 2018 Oct; 308():111-119. PubMed ID: 30017881
[TBL] [Abstract][Full Text] [Related]
17. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
Grover ND; Limaye RP; Gokhale DV; Patil TR
Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
[TBL] [Abstract][Full Text] [Related]
18. The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.
Cataldi M
Curr Neuropharmacol; 2013 May; 11(3):276-97. PubMed ID: 24179464
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of zonisamide against rotenone-induced neurotoxicity.
Condello S; Currò M; Ferlazzo N; Costa G; Visalli G; Caccamo D; Pisani LR; Costa C; Calabresi P; Ientile R; Pisani F
Neurochem Res; 2013 Dec; 38(12):2631-9. PubMed ID: 24142350
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
